CN1141143C - Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application - Google Patents
Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application Download PDFInfo
- Publication number
- CN1141143C CN1141143C CNB021105782A CN02110578A CN1141143C CN 1141143 C CN1141143 C CN 1141143C CN B021105782 A CNB021105782 A CN B021105782A CN 02110578 A CN02110578 A CN 02110578A CN 1141143 C CN1141143 C CN 1141143C
- Authority
- CN
- China
- Prior art keywords
- vaccine
- saponin
- ginseng total
- monomer
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention discloses a purpose of the immunological adjuvant of the vaccine of ginseng total saponin or monomer saponin Rb1. The ginseng total saponin or the monomer saponin Rb1 is used as the immunological adjuvant of the vaccine. The ginseng total saponin, or the monomer saponin Rb1 and aluminum hydroxide are mixed to be used as the immunological adjuvant of the vaccine. Compared with the aluminum hydroxide adjuvant, the present invention has the following advantages that 1) the side effect of the ginseng total saponin and the monomer saponin Rb1 is small; 2) the vaccine in which the ginseng total saponin or the monomer saponin Rb1 as the immunological adjuvant can be preserved under the condition of low temperature freezing, and the validity period of the vaccine is extended; 3) the ginseng total saponin or the monomer saponin Rb1 is used as the immunological adjuvant to prepare the vaccine, a method is simple and convenient, and quality is easy to control; 4) after the ginseng total saponin or the monomer saponin Rb1, and the vaccine containing aluminum hydroxide are mixed, new vaccine is prepared, and the new vaccine can induce a body to generate high body fluid immunological response and body fluid immunological response as compared with the original vaccine.
Description
Technical field
The present invention relates to the purposes that Radix Ginseng total saponins or saponin monomer Rb1 are used to prepare vaccine immunity adjuvant.
Background technology
When vaccine adjuvant is used in combination with antigen, can enhancing body to antigen immune response, on production of vaccine, have purposes widely.How using the effect that immunological adjuvant improves immunity inoculation, is a focus on the modern medicine study.Glenny has used aluminium hydroxide gel as since as immunological adjuvant from the twenties, and the aluminium glue adjuvant is still so far and uniquely can uses a class adjuvant through the FDA approval on human body.But such adjuvant has many shortcomings, for example: 1) mainly improve humoral immune reaction, and pair cell immunoreation effect is little; 2), and then cause anaphylaxis easily owing to increased the IgE production of antibodies; 3) local irritation is bigger.
(1,3)Broad research has been carried out for seeking new adjuvant in countries in the world in recent years, and has obtained certain progress.On China veterinary, widely apply as oil emulsion adjuvant, but because of its local excitation and difficult in vivo degraded, many developed countries forbid using on edible animal.In order to promote the outlet of China's animal product, the use of oily adjuvant will be subjected to respective limits.Synthetic muramyldipeptide (MDP) has adjuvant effect preferably, still is in conceptual phase at present.Quil-A (a kind of Saponin that extracts from the soapbark of South America) has very strong adjuvant effect, but because of its toxic action and local response, can not be in clinical practice.(2) report of the useful propolis adjuvant of China, but the propolis composition is extremely complicated, is difficult to quality control, only uses on some animal vaccines at present.
Summary of the invention
The purpose of this invention is to provide a kind of Radix Ginseng total saponins of raising immune effect of vaccine easy, that side effect is little or the purposes that saponin monomer Rb1 is used to prepare vaccine immunity adjuvant.
Radix Ginseng total saponins or saponin monomer Rb1 are used to prepare vaccine immunity adjuvant.
Compare with traditional aluminum hydroxide adjuvant, the present invention has following advantage:
1) side effect of Radix Ginseng total saponins and saponin monomer Rb1 is little.For example, inject 6 cow heads, only have an example slight swelling to occur in the injection site and disappearance within 48 hours with oralbumin (OVA) the solution musculi colli that contains Radix Ginseng total saponins.And with OVA injection of solution 6 cow heads of aluminium hydroxide, then swelling all appears in this 6 cow head in the injection site, and just disappears after continuing for 2 weeks.With 4 of the staphylococcus aureus vaccine subcutaneous injection Cavia porcelluss that contains Radix Ginseng total saponins or saponin monomer Rb1, there is no systemic adverse reactions and local irritant effect.And visible injection site swelling when doing the staphylococcus aureus vaccine subcutaneous injection Cavia porcellus of adjuvant with aluminium hydroxide.
2) vaccine of making adjuvant with Radix Ginseng total saponins or saponin monomer Rb1 can be preserved under the condition that low temperature freezes, and prolongs the effect duration of vaccine.The vaccine that with the aluminium hydroxide gel is adjuvant then can not freeze by low temperature, otherwise can destroy colloidal state, and therefore, the effect duration of vaccine is shorter relatively.
3) be that adjuvant prepares vaccine with Radix Ginseng total saponins or monomer Rb 1, method is easy, and quality is controlled easily.And be that adjuvant prepares vaccine with the aluminium hydroxide gel, bad if preparation or storage condition are grasped, can make aluminium hydroxide lose colloidal state, adjuvant effect weakens.
4) novel vaccine of making after the mixing of the vaccine of Radix Ginseng total saponins or saponin monomer Rb1 and aluminium hydroxide can induce body to produce higher humoral immunoresponse(HI) and humoral immunoresponse(HI) than former vaccine.This method can improve humoral immunization and the cellullar immunologic response of body to vaccine injection.
Description of drawings
Accompanying drawing is embodiment 3 contrast figure as a result.
The specific embodiment
The present invention directly is mixed and made into vaccine with normal saline solution and the antigen of Radix Ginseng total saponins or saponin monomer Rb1, also the normal saline solution of Radix Ginseng total saponins or saponin monomer Rb1 and the vaccine of aluminium hydroxide can be mixed and made into a kind of new vaccine.
1) Radix Ginseng total saponins or panaxoside monomer Rb 1 are dissolved in normal saline, make Radix Ginseng total saponins and panaxoside monomer Rb 1 solution.Deactivation staphylococcus aureus and ginsenoside's solution are mixed, make the staphylococcus aureus vaccine that contains different adjuvants.Every milliliter of vaccine contains 10
6The deactivation staphylococcus aureus.
2) with 1 milliliter of subcutaneous injection Cavia porcellus of above-mentioned vaccine.Inject again 1 time with same procedure after 2 weeks.2 weeks before injection for the first time and after the 2nd injection, blood sample collection, separation of serum.Detect serum IgG content with agar diffusion method.IgG content raises and illustrates that humoral immune reaction strengthens.
The results are shown in Table.The vaccine that contains the ginsenoside can be induced higher humoral immune reaction than matched group.
| Grouping | The Cavia porcellus number | Each milliliter vaccine adjuvant content | Antibody (IgG) recruitment (injecting the back detection of 2 weeks for the last time) |
| 1 | 3 | Radix Ginseng total saponins 4mg | 43.9％ |
| 2 | 3 | Radix Ginseng total saponins 8mg | 46.7％ |
| 3 | 3 | Ginsenoside Rb1 2mg | 61.0％ |
| 4 | 3 | No adjuvant | 30.0％ |
1) Radix Ginseng total saponins or panaxoside monomer Rb 1 are dissolved in normal saline, concentration is respectively 4mg/ milliliter and 1mg/ milliliter.With the filter membrane degerming of solution by 0.22 micron.Room temperature is deposited, and is standby.
2) with after 5 milliliters of commodity deactivation staphylococcus aureus vaccines (aluminium hydroxide adjuvant) and 1 milliliter of Radix Ginseng total saponins solution or 1 milliliter of mixing of panaxoside monomer Rb 1 solution, musculi colli injection milch cow.Inject again 1 time with same procedure after 2 weeks.After 2 weeks, gather the milch cow blood sample, the separating blood lymphocyte is done lymphocyte transformation test.Calculate to drench and change index.Drenching changes the high explanation of index cell immune response height.
The results are shown in Table.By table as seen, after vaccine added Radix Ginseng total saponins or panaxoside monomer Rb 1, cell immune response strengthened.
Embodiment 3
| Grouping | The milch cow number | Con A | PWM | Staphylococcus aureus antigen |
| Deactivation staphylococcus aureus vaccine (aluminium hydroxide adjuvant) | 6 | 2.02±0.49 | 1.89±0.50 | 1.96±0.57 |
| Deactivation staphylococcus aureus vaccine (aluminium hydroxide adjuvant)+Radix Ginseng total saponins 4mg | 6 | 3.30±0.38 | 2.86±0.59 | 2.89±0.33 |
| Deactivation staphylococcus aureus vaccine (aluminium hydroxide adjuvant)+ginsenoside Rb1 1mg | 6 | 4.29±0.50 | 3.36±0.24 | 338±0.91 |
1) assist agent solution or the colloid of the following different content of preparation:
A) 8 milligrams of Radix Ginseng total saponins/ml solns;
B) 16 milligrams of Radix Ginseng total saponins/ml solns;
C) aluminium hydroxide gel and Radix Ginseng total saponins mixed liquor (aluminium hydroxide glue 6% and Radix Ginseng total saponins 8 mg/ml);
D) 6% aluminium hydroxide gel.
2) pig parvoviral antigen (5120 HAU/milliliter) is mixed and made into the vaccine that contains different adjuvants with above-mentioned a, b, c or d liquid at 1: 1.
3) with above-mentioned vaccine immunity Cavia porcellus.2 milliliters of the 1st every animal subcutaneous injections.After 3 weeks, use with quadrat method and inject again 1 time.After 2 weeks, blood sample collection, separation of serum detects PPV antibody titer in the antiserum with blood clotting inhibition method.
The results are shown in Figure.
Matched group: do not contain any adjuvant; 1 group: contain Radix Ginseng total saponins 4mg; 2 groups: contain Radix Ginseng total saponins 8mg; 3 groups: contain 3% aluminium hydroxide gel; 4 groups: contain 4 milligrams of 3% aluminium hydroxide gel and Radix Ginseng total saponinss.
Claims (1)
1. Radix Ginseng total saponins or saponin monomer Rb1 are used to prepare the purposes of vaccine immunity adjuvant, it is characterized in that Radix Ginseng total saponins or saponin monomer Rb1 are used to prepare vaccine immunity adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021105782A CN1141143C (en) | 2002-01-16 | 2002-01-16 | Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021105782A CN1141143C (en) | 2002-01-16 | 2002-01-16 | Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1367022A CN1367022A (en) | 2002-09-04 |
| CN1141143C true CN1141143C (en) | 2004-03-10 |
Family
ID=4741151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021105782A Expired - Fee Related CN1141143C (en) | 2002-01-16 | 2002-01-16 | Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1141143C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100339083C (en) * | 2004-02-24 | 2007-09-26 | 范敏华 | Progesterone liquid capsule and its preparation method |
| CN100398151C (en) * | 2005-02-18 | 2008-07-02 | 浙江大学 | Ginsenoside nano microparticle and its preparing method and use |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101185757B (en) * | 2007-10-09 | 2011-04-06 | 浙江大学 | Vaccine containing composite adjuvant and preparation method thereof |
| CN102133396B (en) | 2011-03-16 | 2013-10-16 | 中国人民解放军第三〇二医院 | Vaccine injection and preparation method thereof |
| CN104857511B (en) * | 2015-02-13 | 2018-03-30 | 浙江大学 | Thinner for vaccine containing panaxoside |
| CN111346224B (en) * | 2018-12-24 | 2023-12-08 | 洛阳赛威生物科技有限公司 | Immunoadjuvant composition, preparation method and application thereof |
-
2002
- 2002-01-16 CN CNB021105782A patent/CN1141143C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100339083C (en) * | 2004-02-24 | 2007-09-26 | 范敏华 | Progesterone liquid capsule and its preparation method |
| CN100398151C (en) * | 2005-02-18 | 2008-07-02 | 浙江大学 | Ginsenoside nano microparticle and its preparing method and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1367022A (en) | 2002-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| França et al. | Effects of Momordica charantia L. on the blood rheological properties in diabetic patients | |
| CN1141143C (en) | Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application | |
| WO2015101271A1 (en) | Vegetable oil adjuvant containing ginsenoside and preparation method and application thereof | |
| TW201517930A (en) | Use of starfish extract for manufacture of composition for enhancing secretion of collagen | |
| CN105037577A (en) | Procoagulant blackberry seed polysaccharide, and extraction separation method and application thereof | |
| Yang et al. | The Taishan Robinia pseudoacacia polysaccharides enhance immune effects of rabbit haemorrhagic disease virus inactivated vaccines | |
| CN102294026A (en) | Milk cow streptococcal mastitis inactivated vaccine and preparation method thereof | |
| CN109134613A (en) | It is a kind of promote vaccine immunity reaction bursa of Fabricius heptapeptide and its application | |
| US9060963B2 (en) | Anti-inflammatory hydrolysate of C. versicolor | |
| CN102370977A (en) | Novel vaccine adjuvant and application | |
| CN109336987A (en) | A kind of hickory chick and bolete compound Thick many candies and preparation method and medical application | |
| WO2023036203A1 (en) | Cs-4 fermented mycelium heteropolysaccharide, preparation method therefor and use thereof | |
| JP6648279B2 (en) | Immune enhancer, foot-and-mouth disease inactivated vaccine and method for producing the same | |
| CN106381279B (en) | A kind of extracellular polysaccharide of bacteria, preparation method and its application | |
| CN103450354B (en) | Huangqi glycoprotein (HQGP) and preparation method and application thereof | |
| Ohiri et al. | Stabilizing ability and anti-sickling potentials of Ganoderma lucidum decoction extract on human HbS erythrocytes membrane | |
| CN116948961B (en) | Leukocyte extract, anti-wrinkle tightening cream and preparation method thereof | |
| Keahey | The pathogenesis of urticaria | |
| Scherr et al. | A new alginate adjuvant | |
| CN108948185A (en) | The rabbit alliin antibody that alliin antigen and its immune response obtain | |
| CN1931363A (en) | Toxoplasma metabolic secretion antigen vaccine and its prepn process | |
| CN108030918B (en) | Immunostimulating compound and preparation method and application thereof | |
| CN100484571C (en) | Application of semen momordicae extract containing triterpene saponin | |
| CN1183157C (en) | Method for distilling active protein liquid of scorpion | |
| CN1623557A (en) | Application of gold ear mycelium polysaccharide for lowering blood fat and blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040310 Termination date: 20110116 |